UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence

Current HIV/AIDS reports, 2016-10, Vol.13 (5), p.289-296

2016

Volltextzugriff (PDF)

Cystatin C and baseline renal function among HIV-infected persons in the SUN Study

AIDS research and human retroviruses, 2012-02, Vol.28 (2), p.148-155

2012

Volltextzugriff (PDF)

Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness

The Journal of infectious diseases, 2020-10, Vol.222 (Supplement_5), p.S365-S375

2020

Volltextzugriff (PDF)

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

PloS one, 2018-04, Vol.13 (4), p.e0195897-e0195897

2018

Volltextzugriff (PDF)

Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects

The Journal of infectious diseases, 2013-03, Vol.207 (5), p.749-758

2013

Volltextzugriff (PDF)

The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screening

Journal of nuclear cardiology, 2018-06, Vol.25 (3), p.884-886

2018

Volltextzugriff (PDF)

Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population

Clinical infectious diseases, 2007-03, Vol.44 (5), p.726-734

2007

Volltextzugriff (PDF)

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

The Journal of infectious diseases, 2019-05, Vol.219 (11), p.1755-1765

2019

Volltextzugriff (PDF)

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Open forum infectious diseases, 2015-04, Vol.2 (2), p.ofv040-ofv040

2015

Volltextzugriff (PDF)

Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected Persons

Clinical infectious diseases, 2005-10, Vol.41 (7), p.1045-1048

2005

Volltextzugriff (PDF)

Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States

Sexually transmitted diseases, 2012-02, Vol.39 (2), p.154-160

2012

Volltextzugriff (PDF)

Perceptions of alcohol risk among individuals living with HIV

AIDS care, 2011-01, Vol.23 (1), p.107-112

2011

Volltextzugriff (PDF)

STD/HIV risk among adults in the primary care setting: are we adequately addressing our patients' needs?

Sexually transmitted diseases, 2011-01, Vol.38 (1), p.30-32

2011

Volltextzugriff (PDF)

Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy

AIDS research and human retroviruses, 2012-03, Vol.28 (3), p.259-264

2012

Volltextzugriff (PDF)

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

The New England journal of medicine, 2015-08, Vol.373 (8), p.714-725

2015

Volltextzugriff (PDF)

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Open forum infectious diseases, 2016-12, Vol.3 (1)

2016

Volltextzugriff (PDF)

Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care

Journal of the International Association of Providers of AIDS Care, 2013-03, Vol.12 (2), p.138-141

2013

Volltextzugriff (PDF)

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial

Annals of internal medicine, 2015-06, Vol.162 (12), p.815-824

2015

Volltextzugriff (PDF)

Metabolic complications of HIV infection and its therapies

Topics in antiviral medicine, 2014-06, Vol.22 (3), p.651-654

Overton, Edgar Turner

2014

Volltextzugriff (PDF)

Chlamydia Vaccination: Parent Opinions and Implications for Future Promotion Programs

Sexually transmitted diseases, 2022-11, Vol.49 (11), p.745-749

2022

Volltextzugriff (PDF)

Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV

AIDS research and human retroviruses, 2022-09, Vol.38 (9), p.735-742

2022

Volltextzugriff (PDF)

Perceived Need and Acceptance of a Future Chlamydia Vaccine Among Health Care Providers

Sexually transmitted diseases, 2022-11, Vol.49 (11), p.740-744

2022

Volltextzugriff (PDF)

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

The Journal of infectious diseases, 2014-07, Vol.210 (1), p.99-110

2014

Volltextzugriff (PDF)

Sometimes, More Is Better

The Journal of infectious diseases, 2012-03, Vol.205 (5), p.697-699

Overton, Edgar Turner

2012

Volltextzugriff (PDF)

Identifying Risk Factors for HIV-Associated Neurocognitive Disorders Using the International HIV Dementia Scale

Journal of neuroimmune pharmacology, 2013-12, Vol.8 (5), p.1114-1122

2013

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(52)

Sprache

Englisch
(52)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence

Cystatin C and baseline renal function among HIV-infected persons in the SUN Study

Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness

Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial

Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects

The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screening

Metabolic Syndrome in HIV-Infected Patients from an Urban, Midwestern US Outpatient Population

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Undetectable Plasma HIV RNA Load Predicts Success after Hepatitis B Vaccination in HIV-Infected Persons

Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States

Perceptions of alcohol risk among individuals living with HIV

STD/HIV risk among adults in the primary care setting: are we adequately addressing our patients' needs?

Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Efavirenz Outperforms Boosted Atazanavir among Treatment-Naive HIV-1-Infected Persons in Routine Clinical Care

Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial

Metabolic complications of HIV infection and its therapies

Chlamydia Vaccination: Parent Opinions and Implications for Future Promotion Programs

Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV

Perceived Need and Acceptance of a Future Chlamydia Vaccine Among Health Care Providers

Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles

Sometimes, More Is Better

Identifying Risk Factors for HIV-Associated Neurocognitive Disorders Using the International HIV Dementia Scale

Aktive Filter

Suchergebnisse filtern